Syndicate content

Lasker Basic Medical Research Award 2017 Goes to Michael N. Hall for Discoveries Concerning Nutrient-Activated TOR Proteins and Their Central Role in the Metabolic Control of Cell Growth

The 2017 Albert Lasker Basic Medical Research Award honors a scientist who discovered the nutrient-activated TOR proteins and their central role in the metabolic control of cell growth. By showing that the TOR system adjusts cell size in response to the availability of raw materials, Dr. Michael N. Hall (photo) (Biozentrum, University of Basel, Switzerland) revealed an unanticipated linchpin of normal cell physiology. TOR balances constructive and destructive activities to match accumulation of cell mass with nutrient supply and other growth signals, such as hormones. Disruption of the TOR network contributes to numerous human illnesses, including diabetes and cancer, and has been implicated in a wide range of other age-related disorders. The story began in the late 1980s, when many researchers were studying the tightly choreographed process by which cells divide. Although scientists recognized that a cell must increase in content and size as part of this process, they were not focused on that aspect. Growth was thought to be spontaneous, so if raw materials such as amino acids and fatty acids were present, the thinking went, cells would manufacture macromolecules such as proteins and lipids. In this scenario, a growth regulator was unnecessary. At that time, Dr. Hall was studying how proteins cross the membrane barrier that separates the main body of the cell, or cytoplasm, from the nucleus, where genes reside. Toward that end, he was exploring how a certain class of drugs (called immunosuppressants) obstruct T-cell activation, the process by which these immune cells rev up and proliferate. Scientists knew that these drugs somehow block transmission of a signal that travels into the nucleus to turn on certain genes. The medicines held great interest because their ability to quash inflammation helps prevent organ rejection after a transplant. Dr. Hall hoped to discern the drugs’ then-murky mechanisms of action by exploiting the experimental power of baker’s yeast. The wisdom of studying an immunosuppressant in this single-celled creature was questionable, given the vast evolutionary distance between humans and yeast. However, one of the drugs, rapamycin (sirolimus), had originally been identified as an anti-fungal agent, so Dr. Hall thought it might prevent yeast, too, from duplicating. The first sign that his bold strategy would flourish emerged when he showed that rapamycin blocks proliferation of yeast cells, the same effect it has on mammalian cells.

To understand how rapamycin works, Dr. Hall wanted to identify proteins with which it interacts. He sought genetic variants of yeast that could divide in the presence of the chemical. Such mutants, he reasoned, might carry alterations in genes that encode rapamycin-binding proteins. The perturbations would render the drug impotent because it would be unable to grab and inactivate its usual molecular quarry.

Two previously unknown genes emerged from this process. Dr. Hall named them TOR1 and TOR2, for target of rapamycin, when he and postdoctoral fellow Joseph Heitman published the results in 1991. Dr. Hall isolated normal versions of the genes and analyzed their sequences, which turned out to encode two closely related proteins. When he engineered yeast to lack both TOR genes, he reported in 1993, the organisms got stuck early in the cell-division cycle, as they do when treated with rapamycin. This mimicry indicated that the drug obliterates TOR activity.

By a year and a half later, four research groups had identified mammalian TOR based on its ability to bind rapamycin. Originally, three of these groups gave the single mammalian TOR, whose sequence resembles those of its two yeast counterparts, a different name, but now it is universally referred to as mTOR. The shared function and structure bolstered the notion that TOR would perform similar tasks across the evolutionary spectrum.

TOR’s sequence established a novel family of kinases, proteins that affix a phosphate chemical group to other molecule(s), but the potential recipients and effects of that deed were unknown, as were the protein’s triggers and restraints. Presumably, TOR fostered an early step of cell division, as cells that lack TOR function arrest at that point in the process.

TOR-deficient cells, however, displayed a perplexing trait. Yeast with flaws in proteins known to promote early steps of cell division swell in size because they accumulate contents without separating into two daughter cells. Yet yeast that lack TOR activity did not grow exceptionally large. This conundrum intrigued Hall, and by unraveling it, he exposed an unexpected regulatory system that governs cell growth.


In 1996, Dr. Hall reported that cells with nonfunctional TOR initiate protein synthesis feebly and generate unusually small quantities of protein. Thus, the cells fail to duplicate not because TOR does a specific job in cell division, but because protein manufacture plummets in general, including for proteins that propel the cell through the division cycle.

As Dr. Hall dug more deeply, he realized that TOR-deficient cells behave as if they are starving. When nutrients are scarce, yeast ramp down their building activities. They subdue protein and most messenger RNA production, remaining alive but metabolically dormant. By all criteria tested, TOR-deprived yeast were stalling out in this limbo-like state. Dr. Hall proposed that normal, intact TOR stimulates cell growth in response to nutrient availability. Several years later, he showed that TOR sits at the crux of a signaling pathway that receives information about nutrient status and sparks downstream events that tailor gene activity in response.

Dr. Hall and others began untangling how TOR tunes protein synthesis and other activities. An explosion of work has established that TOR—in yeast and mammals—encourages macromolecule production in many ways and on multiple levels. In favorable circumstances, it not only incites protein and nucleic acid synthesis, but promotes manufacture of their subunits and assembly of machines such as ribosomes that make them. It also fosters synthesis of lipids, key ingredients of the cell membrane, which must expand as cells bulk up. Conversely, TOR dampens processes that break apart large molecules to recycle their components.

In addition to unveiling TOR’s growth-related deeds, scientists have begun to probe mechanisms by which nutrients influence its behavior. For example, David M. Sabatini (Massachusetts Institute of Technology and Whitehead Institute for Biomedical Research) has shown how amino acids prompt mTOR activation at a particular site inside the cell.


Stimulation of metabolic pathways is a key aspect of growth, but physical changes must also occur. As yeast cells head toward division, a bulge appears at a particular site on their surface. It expands and eventually pinches off to form a new daughter cell. This budding process involves reorganization of internal filaments, composed largely of the protein actin, at a specific location. By molding this framework, the cell thus shapes itself to promote reproduction.

Through numerous strategies, Dr. Hall established that TOR2 controls these actin rearrangements. The initial hint came from the observation that the two TOR genes are not interchangeable, despite significant sequence identity. Dr. Hall’s early genetic experiments showed that TOR2 could substitute for TOR1, but TOR1 could not substitute for TOR2. He proposed that two signaling pathways operate, one shared by TOR1 and TOR2, and one unique to TOR2. The first instructs the cell when to shift into a constructive metabolic mode—when nutrients are plentiful—and the second tells the cell where to grow—at the bud site. In this way, he suggested, the TOR system ensures that growth occurs only at specific times and places.

In 2002, Dr. Hall uncovered the physical basis for these pathways. He identified and characterized two molecular assemblies, distinguished by different protein constituents. The first, TOR Complex 1 (TORC1), contains TOR1 or TOR2 plus a particular combination of other proteins, and it exerts the many metabolic effects associated with TOR; the second, TOR Complex 2 (TORC2), contains TOR2 plus a different combination of proteins, and it executes the actin-associated, TOR2-unique function as well as lipid synthesis and other tasks that can have mechanical influence. This work revealed why TOR2 can signal through both pathways and TOR1 can signal through only one. It also explained why rapamycin foils the shared pathway but not the unique one, as the drug does not bind TORC2.

At this point, only a TORC1-type of complex had surfaced in mammalian cells, but Dr. Hall wondered whether mammalian TORC2 might have eluded detection because of how scientists had been studying TOR function—by adding rapamycin and documenting its effects. If mammalian TORC2 physiology mirrored that of yeast, he reasoned, the strategy would have left TORC2 untouched, as the complex is insensitive to the drug.

Using methods that did not involve rapamycin, Dr. Hall and others showed in 2004 that TORC2 exists in mammalian cells and controls actin remodeling. Like yeast TOR2, the single mTOR forms two distinct complexes, mTORC1 and mTORC2. Evolution has thus retained the dual signaling pathways by which TOR governs cell growth. At some point, the ancestral system picked up additional inputs—hormonal signaling from insulin, for example—and we now know that mTOR helps multicellular creatures coordinate cell growth across a whole body.

Dr. Hall discovered TOR and thus unearthed a master regulator that links resource availability with myriad aspects of metabolism and growth. These processes are essential to all living things, so it is no surprise that TOR touches a tremendous array of human pathological conditions in which some facet of them has gone awry. Scientists are putting these findings to work—developing mTOR inhibitors, for example, for certain cancers. By studying a clinically useful drug in yeast, Dr. Hall illuminated a signaling pathway with profound medical implications for humans.

The above posting was drawn from a Lasker Foundation release authored by Evelyn Strauss.

Please note the related figure in the Lasker release for which a link is provided below.

Key Publications of Michael N. Hall

Heitman, J., Movva, N.R., and Hall, M.N. (1991). Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 253, 905-909.

Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N.R., and Hall, M.N. (1993). Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 73, 585-596.

Barbet, N.C., Schneider, U., Helliwell, S.B., Stansfield, I., Tuite, M.F., and Hall, M.N. (1996). TOR controls translation initiation and early G1 progression in yeast. Mol. Biol. Cell. 7, 25-42.

Beck, T., and Hall, M.N. (1999). The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature. 402, 689-692.
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J.L., Bonenfant, D., Oppliger, W., Jenoe, P., and Hall, M.N. (2002). Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell. 10, 457-468.

Hall, M.N. (2016). TOR and paradigm change: cell growth is controlled. Mol. Biol. Cell. 27, 2804-2806.

González, A., and Hall, M.N. (2017). Nutrient sensing and TOR signaling in yeast and mammals. EMBO J. 36, 397-408.

[Press release]